COMPARING THE TOXIC EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (CELECOXIB AND IBUPROFEN) ON HEART, LIVER, AND KIDNEY IN RATS

Authors

  • Noor D Aziz Department of Clinical Pharmacy, Faculty of Pharmacy, University of Kerbala, Iraq.
  • Mazin H. Ouda Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kerbala, Iraq.
  • Moayad Mijbil Ubaid Department of Biology, Basic Education College, University of Sumer, Iraq.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i6.25487

Keywords:

Celecoxib, Ibuprofen, Toxicity, Biochemical markers, Histopathology, Heart, Liver, Kidney

Abstract

Objective: Nonsteroidal anti-inflammatory drugs (NSAIDs) do not reverse the disease progression, but they provide relief from pain and inflammation by inhibiting cyclooxygenase (COX) enzymes mediating the inflammatory pathway. Our aim was to make a meaningful comparison of both selective and non-selective COX-2 inhibitor to evaluate their toxic effects by measuring biochemical and histological alterations of heart, liver, and kidney.

Methods: This study was conducted on 18 Sprague-Dawley rats of both sexes for 30 days, rats were divided into three groups (control group, ibuprofen group, and celecoxib group) each group included six rats.

Results: The results are revealed that serum level of alanine aminotransferase, aspartate aminotransferase, alkaline phosphates, and total serum bilirubin was significantly increased (p<0.05) in ibuprofen and celecoxib group when compared with control, the highest level in celecoxib group, also serum level of urea was significantly elevated (p<0.05) in ibuprofen group when compared with control and celecoxib groups. Histopathological changes in cardiac tissue represented by vascular congestion and pericardial infiltration which are more prominent in celecoxib group, the changes in liver tissue revealed by vascular congestion and mild portal tract inflammation which is chronic in celecoxib group, while histological alterations in kidney tissue represented by severe vascular congestion with tubular necrosis which is more prominent in ibuprofen group.

Conclusion: Both ibuprofen and celecoxib group have toxic effects on heart, liver, and kidney represented by the biochemical and histopathological findings.

Downloads

Download data is not yet available.

Author Biography

Noor D Aziz, Department of Clinical Pharmacy, Faculty of Pharmacy, University of Kerbala, Iraq.

Department of Clinical Pharmacy

College of Pharmacy

University of Kerbala

References

Ferreira S. Peripheral analgesic sites of action of anti-inflammatory drugs. Int J Clin Pract Suppl 2002;128:2-10.

Mitchell JA, Warner TD. Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharm 1999;128:1121-32.

Brune K. Persistence of NSAIDs at effectsites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin 2007;23:2985-95.

Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci 1992;89:7384-8.

Peniva PT. Non-steroidal anti-inflamatory dugs for topical ophthalmic administration: Contemporary trends. Int J Pharm Pharm Sci 2015;7:13 9.

Scarpignato C, Corradi C, Gandolfi MA, Galmiche JP. A new technique for continuous measurement and recording of gastric potential difference in the rat: Evaluation of NSAID-induced gastrics mucosal damage. J Pharm Toxicol Methods 1995;34:63-72.

Famaey J. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview. Inflamm Res 1997;46:437-46.

Miladiyah I, Jumina J, Haryana SM, Mustofa M. In silico molecular docking of xanthone derivatives as cyclooxygenase-2 inhibitor agents. Int J Pharm Pharm Sci 2017;9:98-104.

Smith WL, Meade EA, DeWitt DL. Interactions of PGH synthase isozymes-1 and-2 with NSAIDs. Ann N Y Acad Sci 1994;744:50-7.

Rainsford K. Ibuprofen pharmacology, efficacy and safety. Inflamm Pharmacol 2009;17:275-342.

Prusakiewicz JJ, Duggan KC, Rouzer CA, Marnett LJ. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry 2009;48:7353-5.

Rudy AC, Knight PM, Brater DC, Hall SD. Stereoselective metabolism of ibuprofen in humans: Administration of R, S-and racemic ibuprofen. J Pharm Exp Ther 1991;259:1133-9.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.

Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.

Lanas A. Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology 2002;41 suppl_1:16-22.

Lanas A, Sopeña F. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin North Am 2009;38:333-52.

García-Alonso V, Titos E, Alcaraz-Quiles J, Rius B, Lopategi A, López-Vicario C, et al. Prostaglandin E2 exerts multiple regulatory actions on human obese adipose tissue remodeling, inflammation, adaptive thermogenesis and lipolysis. PLoS One 2016;11:e0153751.

Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M.Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 2004;316:421-8.

Schönthal A. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 2007;97:1465 8.

Gerald GA. Prostaglandins modulators of inflammation and cardiovascular risk. J Clin Rheumatol 2004;10:S12-S7.

Banchroft JD, Stevens A, Turner DR. Theory and Practice of Histological Techniques. 4th ed. New York, London, San Francisco, Tokyo: Churchillliving Stone; 1996.

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.

Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J 2001;77:548-50.

Vasudevan DM, Sreekumari S. Textbook of Biochemistry for Medical Students. 5th ed. New Delhi: Jaypee BrothersMedical Publishers Ltd.; 2007.

Nasrallah R, Robertson SJ, Karsh J, H´ebert RL. Celecoxib modifies glomerular basement membrane, mesangium and podocytes in OVE26mice, but ibuprofen is more detrimental. Clin Sci 2013;124:685 94.

Published

07-06-2018

How to Cite

Aziz, N. D., M. H. Ouda, and M. M. Ubaid. “COMPARING THE TOXIC EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (CELECOXIB AND IBUPROFEN) ON HEART, LIVER, AND KIDNEY IN RATS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 6, June 2018, pp. 482-5, doi:10.22159/ajpcr.2018.v11i6.25487.

Issue

Section

Original Article(s)